169 related articles for article (PubMed ID: 32884297)
1. MiR-140 Resensitizes Cisplatin-Resistant NSCLC Cells to Cisplatin Treatment Through the SIRT1/ROS/JNK Pathway.
Lin Z; Pan J; Chen L; Wang X; Chen Y
Onco Targets Ther; 2020; 13():8149-8160. PubMed ID: 32884297
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of miR-15b partially reverses the cisplatin resistance of NSCLC through the GSK-3β/MCL-1 pathway.
Lu T; Lu W; Jia C; Lou S; Zhang Y
Adv Clin Exp Med; 2021 Aug; 30(8):849-857. PubMed ID: 34286518
[TBL] [Abstract][Full Text] [Related]
3. Restoration of miR-26b expression partially reverses the cisplatin resistance of NSCLC by targeting tafazzin.
Zang S; Zhao S; Gao X; Li Y; Zhong C; Gao J
Onco Targets Ther; 2019; 12():7551-7560. PubMed ID: 31686855
[TBL] [Abstract][Full Text] [Related]
4. MiR-204 reduces cisplatin resistance in non-small cell lung cancer through suppression of the caveolin-1/AKT/Bad pathway.
Huang G; Lou T; Pan J; Ye Z; Yin Z; Li L; Cheng W; Cao Z
Aging (Albany NY); 2019 Apr; 11(7):2138-2150. PubMed ID: 30981205
[TBL] [Abstract][Full Text] [Related]
5. Metformin partially reverses the carboplatin-resistance in NSCLC by inhibiting glucose metabolism.
Liu Y; He C; Huang X
Oncotarget; 2017 Sep; 8(43):75206-75216. PubMed ID: 29088858
[TBL] [Abstract][Full Text] [Related]
6. MiR-124 changes the sensitivity of lung cancer cells to cisplatin through targeting STAT3.
Qi MM; Ge F; Chen XJ; Tang C; Ma J
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5242-5250. PubMed ID: 31298375
[TBL] [Abstract][Full Text] [Related]
7. miR-124 and miR-142 enhance cisplatin sensitivity of non-small cell lung cancer cells through repressing autophagy
Song X; Kong F; Zong Z; Ren M; Meng Q; Li Y; Sun Z
RSC Adv; 2019 Feb; 9(9):5234-5243. PubMed ID: 35514612
[No Abstract] [Full Text] [Related]
8. TP53TG1 enhances cisplatin sensitivity of non-small cell lung cancer cells through regulating miR-18a/PTEN axis.
Xiao H; Liu Y; Liang P; Wang B; Tan H; Zhang Y; Gao X; Gao J
Cell Biosci; 2018; 8():23. PubMed ID: 29588850
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.
Li JH; Luo N; Zhong MZ; Xiao ZQ; Wang JX; Yao XY; Peng Y; Cao J
Tumour Biol; 2016 Feb; 37(2):2387-94. PubMed ID: 26376998
[TBL] [Abstract][Full Text] [Related]
10. LncRNA FOXD3-AS1 promoted chemo-resistance of NSCLC cells via directly acting on miR-127-3p/MDM2 axis.
Zeng Z; Zhao G; Zhu H; Nie L; He L; Liu J; Li R; Xiao S; Hua G
Cancer Cell Int; 2020; 20():350. PubMed ID: 32742197
[TBL] [Abstract][Full Text] [Related]
11. The PVT1/miR-216b/Beclin-1 regulates cisplatin sensitivity of NSCLC cells via modulating autophagy and apoptosis.
Chen L; Han X; Hu Z; Chen L
Cancer Chemother Pharmacol; 2019 May; 83(5):921-931. PubMed ID: 30859368
[TBL] [Abstract][Full Text] [Related]
12. MiR-133a-3p attenuates resistance of non-small cell lung cancer cells to gefitinib by targeting SPAG5.
Li Q; Wang Y; He J
J Clin Lab Anal; 2021 Jul; 35(7):e23853. PubMed ID: 34057242
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-217 inhibits the proliferation and invasion, and promotes apoptosis of non-small cell lung cancer cells by targeting sirtuin 1.
Li G; Zhong S
Oncol Lett; 2021 May; 21(5):386. PubMed ID: 33777209
[TBL] [Abstract][Full Text] [Related]
14. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-106b-5p regulates cisplatin chemosensitivity by targeting polycystic kidney disease-2 in non-small-cell lung cancer.
Yu S; Qin X; Chen T; Zhou L; Xu X; Feng J
Anticancer Drugs; 2017 Sep; 28(8):852-860. PubMed ID: 28723865
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
17. MiR-29b-3p Reverses Cisplatin Resistance by Targeting COL1A1 in Non-Small-Cell Lung Cancer A549/DDP Cells.
Jia R; Wang C
Cancer Manag Res; 2020; 12():2559-2566. PubMed ID: 32368137
[TBL] [Abstract][Full Text] [Related]
18. miR-324-3p reverses cisplatin resistance by inducing GPX4-mediated ferroptosis in lung adenocarcinoma cell line A549.
Deng SH; Wu DM; Li L; Liu T; Zhang T; Li J; Yu Y; He M; Zhao YY; Han R; Xu Y
Biochem Biophys Res Commun; 2021 Apr; 549():54-60. PubMed ID: 33662669
[TBL] [Abstract][Full Text] [Related]
19. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway.
Xiao XH; He SY
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431
[TBL] [Abstract][Full Text] [Related]
20. A novel circ_MACF1/miR-942-5p/TGFBR2 axis regulates the functional behaviors and drug sensitivity in gefitinib-resistant non-small cell lung cancer cells.
Fan D; Yang Y; Zhang W
BMC Pulm Med; 2022 Jan; 22(1):27. PubMed ID: 34996416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
